glp-1 news nov 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Designing GLP-1 delivery: structural perspectives

Both platforms use licensed providers and compliant pharmacies, but their workflows, support structures, and medication sourcing differ substantially

You can join the waitlist for Retatrutide and complete the consultation form on our website

In the SELECT trial, which included more than 17,000 patients with obesity and cardiovascular disease but not diabetes, semaglutide cut the rate of major cardiac events by 20%

Weight Loss Drugs in Development Doctors are studying new treatment strategies to help people lose weight and to stay at a healthy weight

GLP-1 Medications Approved for Different Uses Not all GLP-1 drugs are FDA-approved for the same thing, and this is important when it comes to insurance coverage

These agents act more specifically, which lowers side effects and improves patient outcomes